Neoplasm Metastasis D009362

Diseases [C] » Neoplasms [C04] » Neoplastic Processes » Neoplasm Metastasis

Description

The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.   MeSH

Hierarchy View

Subtype Terms (6)

Extranodal Extension
 

Lymphatic Metastasis
4 drugs (2 approved, 2 experimental)

Neoplasm Micrometastasis
7 approved drugs

Neoplasm Seeding
1 experimental drug

Neoplasms, Unknown Primary
64 drugs (48 approved, 16 experimental)

Neoplastic Cells, Circulating
46 drugs (40 approved, 6 experimental)


Approved Indicated Drugs (2)

Phase 3 Indicated Drugs (152)

Key: D009362 (146) Subtype (6)

Phase 2 Indicated Drugs (283)

Key: D009362 (267) Subtype (16)

Phase 1 Indicated Drugs (211)

Key: D009362 (202) Subtype (9)


Organization Involved with Phase 4 Indications (75)

Key: D009362 (71) Subtype (4)

Organization Involved with Phase 3 Indications (163)

Key: D009362 (156) Subtype (7)

Organization Involved with Phase 2 Indications (252)

Key: D009362 (245) Subtype (7)

Actelion

Actuate Therapeutics Inc.

AEterna Zentaris

Ain Shams University

AIO-Studien-gGmbH

Allena Pharmaceuticals

Amal Therapeutics

Aposense Ltd.

Apricus Biosciences

Aptose Biosciences Inc.

Aqualis

ARCAGY-GINECO

Array BioPharma

Association of Urogenital Oncology (AUO)

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)

Association pour la Recherche sur le Temps Biologique et la Chronothérapie

Associazione Quovadis

Astellas

Augusta University

AurKa Pharma Inc.

Baylor University

BBB Therapeutics

BioMimetix Pharmaceutical, Inc.

Boston University

Bristol-Myers Squibb

Brown University

California Pacific Medical Center Research Institute

Cancer Research UK

Cancer Trials Ireland

Carolina Research Professionals, LLC

Case Western Reserve University

Catharina Hospital, Eindhoven, The Netherlands

Cedars-Sinai Medical Center

Celsion

Center Eugene Marquis

Central European Society for Anticancer Drug Research (CESAR)

Centre Georges Francois Leclerc

Centre Hospitalier de la Région d'Annecy

Centre hospitalier Purpan

Centre Paul Strauss

Centre Val d'Aurelle

CH Annecy

City of Hope National Medical Center

Cornell University

Covis

Curie Institute

Dalian Medical University

DanTrials ApS, Copenhagen, Denmark

Dartmouth University

Daval International Limited

DEKK-TEC, Inc.

Deltanoid Pharmaceuticals

Dent Neurologic Institute

Dent Neuroscience Research Center

Detroit Clinical Research Center

Developmental Therapeutics Consortium

DFB Pharma

Duke University

Eastern Cooperative Oncology Group

ECOG-ACRIN Cancer Research Group

Eisai

Emory University

Endocyte

Enzon

EPS Corporation

Erasmus University Rotterdam

Esperas Pharma Inc.

Far Eastern Memorial Hospital

Federation Francophone de Cancerologie Digestive

FeRx

Florida International University

Fondazione del Piemonte per l'Oncologia

Fondazione Giovanni Pascale

Gabrail Cancer Center

Gachon University

Gem Pharmaceuticals

General Hospital of Chalkida

Geriatric Oncology Consortium

German Breast Group Forschungs GmbH

German Cancer Research Center

Government of Colombia

Government of Mexico

Government of Taiwan

Gradalis, Inc.

Groupe Oncologie Radiotherapie Tete et Cou

Grupo Español Multidisciplinar de Melanoma

Grupo Espanol Multidisciplinario del Cancer Digestivo

Guangzhou Medical University

Guangzhou University

Harvard University

Hellenic Cooperative Oncology Group

Herantis Pharma Plc.

Herbert Irving Comprehensive Cancer Center

Hopital Paul Brousse

Hospital Infantil Universitario Niño Jesús, Madrid, Spain

Human Stem Cell Institute, Russia

Hyogo Medical University

Imclone

Immodulon Therapeutics Ltd

Immunovative Therapies

Imperial College London

Incyte

Innate Immunotherapeutics

Institut Bergonié

Institut Hospitalier Franco-Britannique

Institut Paoli-Calmettes

Institut Sainte Catherine

Intergroupe Francophone de Cancerologie Thoracique

Introgen Therapeutics

Istituto Superiore di Sanità

Italian Trial in Medical Oncology

James Graham Brown Cancer Center

Jilin University

Jyoti Clinical and Pathological Laboratory

Kadmon

KAI Pharmaceuticals

Kaohsiung Medical University

Kliniken Nordoberpfalz AG Klinikum Weiden Medizinische Kliniken I

Klinikum Oldenburg GmbH

Korean Urological Oncology Society

Kyushu University

Lycera Corp.

Mario Negri Institute

Mary Crowley Cancer Center

Mayo Clinic

Medical College of Wisconsin

MediGene

MedSIR

Melanoma Institute Australia

Merck KGaA

Methodist Cancer Center, Houston, Texas

Mirati Therapeutics Inc.

Nanchang University

Nanobiotix

National Cancer Center, Korea

National Cheng Kung University

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Taiwan University

Netherlands Cancer Institute

New York University

Niigata University Medical & Dental Hospital

Northwestern University

Norwegian University of Science and Technology

Ocellaris Pharma, Inc.

Ohio State University

OHSU Knight Cancer Institute

Onxeo

Opexa Therapeutics

Osaka City University

Osaka University

Oslo Metropolitan University

Ospedale S. Giovanni Bellinzona

Peter MacCallum Cancer Centre

PETHEMA Foundation

Philogen S.p.A.

Phoenix Molecular Imaging

PhytoHealth Corporation

Point Therapeutics

PRACS

Providence Health & Services

Radboud University

Rainier Clinical Research Center

Reata Pharmaceuticals, Inc.

Repos Pharma AB

Rongjie Tao

Royal Marsden Hospital NHS Trust

Rutgers University

RWTH Aachen University

Saint-Joseph University

Shaheed Beheshti Medical University

Shanghai EpimAb Biotherapeutics Co., Ltd.

Shanxi Medical University

Simcere Pharmaceutical Co., Ltd

Southwest Oncology Group

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

State University of New York, Buffalo

Stem Cell Medicine Ltd.

St. Jude Children's Hospital

Technical University of Dresden

Technion University

Temple University

The Adelaide and Meath Hospital

The First People's Hospital of Lianyungang

The Parker Institute

Tohoku University

Translational Research Informatics Center, Kobe, Hyogo, Japan

Trans Tasman Radiation Oncology Group

TriHealth

Tsukuba University

Tulane University

UNICANCER

Universidad Complutense de Madrid

Université catholique de Louvain

University of Alabama, Birmingham

University of Arizona

University of Bern

University of Brescia

University of Buenos Aires

University of Burgundy

University of Calgary

University of California, Davis

University of California, Los Angeles

University of California, San Diego

University of California, San Francisco

University of Cantabria

University of Chicago

University of Cincinnati

University of Florida

University of Gothenburg

University of Grenoble

University of Groningen

University of Hamburg

University of Heidelberg

University of Helsinki

University of Iowa

University of Lausanne

University of Leicester

University of Ljubljana

University of Louisville

University of Magdeburg

University of Maryland

University of Medicine and Dentistry of New Jersey

University of Michigan

University of Milan

University of Minnesota

University of Montreal

University of Nebraska

University of Nice Sophia Antipolis

University of North Carolina at Chapel Hill

University of Oslo

University of Pittsburgh

University of Regensburg

University of Reims

University of Rochester

University of Sao Paulo

University of Southern California

University of South Florida

University of Stavanger

University of Toronto

University of Tuebingen

University of Utah

University of Vienna

University of Western Brittany

Uppsala University

US Oncology

Vanderbilt University

Vastra Gotaland Region

Vedanta Biosciences, Inc.

Wayne State University

Wu Jieping Medical Foundation

YM Biosciences

Zagazig University

Organization Involved with Phase 1 Indications (98)

Key: D009362 (95) Subtype (3)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.